In the present study, in vitro cytotoxicity and in vivo therapeutic efficacy of the alpha-emitting PSMA radioligand 212Pb-NG001 were investigated in two prostate cancer cell lines expressing different levels of PSMA. This evidence concerns the gene FOLH1 and prostate carcinoma.